Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II trial of IMO-2125 in combination with ipilimumab and nivolumab in patients with multiple tumor types including non-small cell lung cancer, melanoma, squamous cell carcinoma of the head and neck and urothelial carcinoma.

Trial Profile

Phase I/II trial of IMO-2125 in combination with ipilimumab and nivolumab in patients with multiple tumor types including non-small cell lung cancer, melanoma, squamous cell carcinoma of the head and neck and urothelial carcinoma.

Planning
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2018

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Tilsotolimod (Primary)
  • Indications Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Nov 2018 According to the Idera Pharmaceuticals media release, The principal investigator initiating this trial is Aurelien Marabelle, MD, PhD, Clinical Director of the Cancer Immunotherapy Program at Institut Gustave Roussy, Villejuif, France.
    • 23 Apr 2018 New trial record
    • 16 Apr 2018 According to the Idera Pharmaceuticals media release, Pillar Partners will provide funding and Idera will provide drug IMO-2125 to conduct this trial. Aurelien Marabelle is the principal investigator for this investigator initiated trial and this trial is expected to initiate before the end of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top